Skip to main content

Full text of "USPTO Patents Application 09804625"

See other formats


PATENT 
Customer No. 22,852 
Attorney Docket No. 08702.0039-02000 

AMENDMENTS TO THE CLAIMS: 

This listing of claims will replace all prior versions and listings of claims in the 
application: 

1-23. (Cancelled) 

24. (Currently amended): An isolated polynucleotide comprising: 

a) nucleotides 1 202 through 1 543 of Figure 2; 

b) nucleotide 1 252 through 1 543 of Figure 2; 

c) nucleotides encoding amino acids 283 through 396 of Figure 2; or 

d) nucleotides encoding amino acids 299 through 396 of Figure 2[[;]] 

e) natural l y occurr i ng a lleli c variants of a) through d) . 

25. (Previously presented): An isolated polynucleotide comprising nucleotides 
1202 through 1543 of Figure 2. 

26. (Previously presented): An isolated polynucleotide comprising nucleotides 
1252 through 1543 of Figure 2. 

Claims 27-28 (Cancelled) 

29. (Previously presented): An isolated polynucleotide comprising nucleotides 
encoding amino acids 283 through 396 of Figure 2. 

30. (Previously presented): An isolated polynucleotide comprising nucleotides 
encoding amino acids 299 through 396 of Figure 2. 

31-32. (Cancelled) 

33. (Currently amended): An isolated polynucleotide comprising a 
polynucleotide that hybridizes und e r string e nt cond i t i ons to a polynucleotide 
complementary to a polynucleotide comprising nucleotides 1252 to 1543 of Figure 2 



-10- 



PATENT 
Customer No. 22,852 
Attorney Docket No. 08702.0039-02000 

under the following conditions: incubation at 65°C in standard hybridization buffer (6X 

SSC. 5X Denhardt's solution. 0.01 M EDTA. 0.5% SDS) and washing at 65°C in 0.2X 

SSC. 0.1% SDS of c l a i m 2A , wherein said isolated polynucleotide encodes a protein 

characterized by the ability to induce the formation of cartilage and/or bone tissue. 

34. (Cancelled) 

35. (Previously presented): A vector comprising a polynucleotide of claim 24 
in operative association with an expression control sequence therefore. 

36. (Previously presented): A vector comprising a polynucleotide of claim 33 
in operative association with an expression control sequence therefore. 

37. (Cancelled) 

38. (Previously presented): A host cell transformed with a vector of claim 35. 

39. (Previously presented): A host cell transformed with a vector of claim 36. 

40. (Cancelled) 

41 . (Previously presented): An isolated polynucleotide comprising s ele ct e d 
from tho group conoist i ng of ATCC deposit d e posits 40345 and ^10312 . 

42. (Currently amended): A method for producing a bone morphogenetic 
protein- 2 prot ei n , said method comprising the steps of: 

a) culturing a host cell transformed with a polynucleotide of claim 33, 
and 

b) recovering said bone morphogenetic protein 2 prote i n . 
43-49. (Cancelled) 



-11-